Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database
Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Post-marketing safety of these agents is understudied, especially in the elderly.
This study aimed to compare, according to age, the adverse drug reactions (ADRs) of targeted therapies used for mCRC in real life.
Patients and Methods
An extraction of VigiBase, which contains World Health Organization individual case safety reports (ICSRs), was performed. All ADR reports with aflibercept, bevacizumab, cetuximab, panitumumab, or regorafenib used in CRC were considered. For all drugs, chi-square tests were used to compare frequencies of serious ADRs between patients aged ≥75 and <75 years. For selected ADRs and each drug, the drug-ADR association compared to other anticancer drugs was estimated through the proportional reporting ratio (PRR) in both age groups.
There were 21,565 ICSRs included, among which 74% were serious and 11% were fatal. Median age was 64 years (Inter Quartile Range = 56–71) and 15% of patients were aged ≥75; 57% were male. Serious ICSRs accounted for 47,292 ADRs. Neutropenia was not more reported in elderly for all drugs while diarrhea was more reported in elderly for panitumumab. Cardiac disorders were more reported in elderly patients, in particular heart failure, especially for bevacizumab, cetuximab, and regorafenib, as were respiratory, thoracic, and mediastinal disorders. Most of PRR were not different between the two groups, except encephalopathies, which were significantly associated with bevacizumab in the elderly only.
ADRs related to targeted therapies used for mCRC treatment were different across age groups; yet, not systematically more reported or worse in elderly patients. Selected elderly patients could, therefore, be treated with these targeted therapies.
The authors would like to thank the Uppsala Monitoring Centre (UMC) that provided and gave permission to use the data analyzed in the present study. The authors are indebted to the National Pharmacovigilance Centers that contributed data. The opinions and conclusions in this study are not necessarily those of the various centers or of the WHO. The authors would like to acknowledge Camilla Westerberg for help with extracting data.
Compliance with Ethical Standards
No funding source.
Conflict of Interest
AG, PC, MR, AFR, GMS declare that they have no conflict of interest. AP coordinates a Pharmacoepidemiology platform granted by ANSM through a 4-year convention (2015–2018), the DRUGS-SAFE project. It aims at providing the ANSM with studies and tolls for the assessment of drugs in real life settings. This work is not part of the DRUGS-SAFE project. MA and PN participate in the DRUGS-SAFE project. TA received personal fees from Roche, Novartis, Sanofi, Pierre Fabre, Halio DX, BMS, and Ipsen grants from Bayer, outside the submitted work.
- 1.Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD. Based on November 2015 SEER data submission, posted to the SEER web site, April 2016. http://seer.cancer.gov/csr/1975_2013/sections.html Accessed 15 June 2017.
- 7.Gouverneur A, Salvo F, Berdaï D, et al. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. J Geriatr Oncol. 2017; https://doi.org/10.1016/j.jgo.2017.08.001.
- 23.Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009;115:2617–29.CrossRefPubMedGoogle Scholar
- 24.Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol. 2012;23:1531–6.CrossRefPubMedGoogle Scholar
- 35.Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16:761–7.Google Scholar